Novel therapies in Hepatitis C virus. Preface.
作者信息
Pockros Paul J
机构信息
Division of Gastroenterology and Hepatology, The Scripps Research Institute, La Jolla, CA 92037, USA.
出版信息
Clin Liver Dis. 2009 Aug;13(3):xiii. doi: 10.1016/j.cld.2009.06.001.
PMID:19628152
Abstract
摘要
相似文献
1
Novel therapies in Hepatitis C virus. Preface.丙型肝炎病毒的新型疗法。前言。
Clin Liver Dis. 2009 Aug;13(3):xiii. doi: 10.1016/j.cld.2009.06.001.
2
Rapid virological response to peginterferon and ribavirin for hepatitis C genotype 1: the role of weight-based ribavirin exposure.聚乙二醇干扰素和利巴韦林治疗丙型肝炎基因1型的快速病毒学反应：基于体重的利巴韦林暴露量的作用
Hepatology. 2008 Sep;48(3):1019-20; author reply 1020-1. doi: 10.1002/hep.22434.
3
Optimal dosage of ribavirin.利巴韦林的最佳剂量。
Hepatology. 2010 Sep;52(3):1174. doi: 10.1002/hep.23742.
4
[Genotype 1 superresponder treat for only 24 weeks].[基因型1超反应者仅治疗24周]
MMW Fortschr Med. 2005 Dec 15;147(51-52):69.
5
Sofosbuvir, pegylated interferon, and ribavirin for retreatment of hepatitis C virus genotype 1b following sofosbuvir and ledipasvir failure.索磷布韦、聚乙二醇干扰素和利巴韦林用于索磷布韦和来迪帕司韦治疗失败后的丙型肝炎病毒1b型再治疗。
Hepatology. 2018 May;67(5):2049-2050. doi: 10.1002/hep.29667. Epub 2018 Mar 25.
6
Treatment duration for genotypes 2 and 3: still confusing after all these years.2型和3型基因型的治疗时长：这么多年来仍然令人困惑。
J Clin Gastroenterol. 2010 Sep;44(8):527-8. doi: 10.1097/MCG.0b013e3181e0b1ce.
7
[Peginterferon-alfa-2b or -alfa-2a and ribavirin combined treatment in hepatitis C infection].聚乙二醇干扰素-α-2b或-α-2a与利巴韦林联合治疗丙型肝炎感染
Orv Hetil. 2010 Feb 14;151(7):271-3. doi: 10.1556/OH.2010.28801.
8
Interferon/pegylated interferon and ribavirin in HCV-associated kidney disease with or without cryoglobulinemia.干扰素/聚乙二醇化干扰素与利巴韦林用于治疗伴有或不伴有冷球蛋白血症的丙型肝炎病毒相关性肾病。
J Hepatol. 2006 Feb;44(2):432-3; author reply 433. doi: 10.1016/j.jhep.2005.10.020. Epub 2005 Nov 21.
9
Scleromyxedema secondary to hepatitis C virus and successfully treated with antiviral therapy.
Dermatol Online J. 2015 Sep 17;21(9):13030/qt1vt8c3vt.
10
Predicting treatment outcome following 24 weeks peginterferon alpha-2a/ribavirin therapy in patients infected with HCV genotype 1: utility of HCV-RNA at day 0, day 22, day 29, and week 6.预测丙型肝炎病毒1型感染患者接受聚乙二醇干扰素α-2a/利巴韦林治疗24周后的治疗结果：第0天、第22天、第29天和第6周时丙型肝炎病毒核糖核酸的效用
Hepatology. 2007 Jan;45(1):258-9. doi: 10.1002/hep.21505.
Zotero 插件